SCHEMBL18399979

SCHEMBL18399979

CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@@]2(O)[C@@H](C=C(CO)C[C@]3(O)C(=O)C(C)=C[C@@H]23)C2C(C)(C)[C@@]21O

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 6/20 0.79
PRKCG P05129 6/20 0.79
PRKCB P05771 5/20 0.79
PRKCH P24723 5/20 0.79
PRKCE Q02156 5/20 0.79
PRKCQ Q04759 5/20 0.79
PRKCD Q05655 5/20 0.79
PRKD3 O94806 4/20 0.79
PRKCI P41743 4/20 0.79
PRKCZ Q05513 4/20 0.79
PRKD1 Q15139 4/20 0.79
USP2 O75604 2/20 0.79
TP53 P04637 2/20 0.79
KDM4E B2RXH2 1/20 0.79
ALDH1A1 P00352 1/20 0.79
SMN1; SMN2 Q16637 1/20 0.79
CYP3A4 P08684 1/20 0.79
CYP2C9 P11712 1/20 0.79
TSHR P16473 1/20 0.79
NFKB1 P19838 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26309656 1.00 PRKCA (0.79) PRKCAPRKCGPRKCBPRKCHPRKCE
SCHEMBL2413670 1.00 PRKCA (0.79) PRKCAPRKCGPRKCBPRKCHPRKCE
SCHEMBL31074956 1.00 PRKCA (0.79) PRKCAPRKCGPRKCBPRKCHPRKCE
SCHEMBL258513 1.00 PRKCA (0.79) PRKCAPRKCGPRKCBPRKCHPRKCE
SCHEMBL26310034 1.00 PRKCA (0.79) PRKCAPRKCGPRKCBPRKCHPRKCE
SCHEMBL18622646 1.00 PRKCA (0.79) PRKCAPRKCGPRKCBPRKCHPRKCE
SCHEMBL15725680 1.00 PRKCA (0.79) PRKCAPRKCGPRKCBPRKCHPRKCE
SCHEMBL18629158 1.00 PRKCA (0.79) PRKCAPRKCGPRKCBPRKCHPRKCE
SCHEMBL3516162 1.00 PRKCA (0.79) PRKCAPRKCGPRKCBPRKCHPRKCE
Acetic Acid SCHEMBL10517222 0.98 PRKCA (0.78) PRKCAPRKCGPRKCBPRKCHPRKCE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200207697-A1 Compositions And Methods Of Use Of Phorbol Esters For Treatment of Stroke CHANG RICHARD L (US) 2020-07-02 US disclosed
US-20200207698-A1 Compositions And Methods Of Use Of Phorbol Esters In The Treatment Of Neoplasms CHANG RICHARD L (US) 2020-07-02 US disclosed
US-10369222-B2 Compositions and methods of use of phorbol esters for the treatment of stroke BIOSUCCESS BIOTECH CO., LTD. (US) 2019-08-06 US disclosed
US-20170096386-A1 Compositions And Methods Of Use Of Phorbol Esters For Treatment of Stroke CHANG RICHARD L (US) 2017-04-06 US disclosed
US-20170087112-A1 COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF STROKE BIOSUCCESS BIOTECH CO. LTD. (US) 2017-03-30 US disclosed
US-9550722-B2 Compositions and methods of use of phorbal esters for the treatment of stroke BIOSUCCESS BIOTECH CO. LTD. (US) 2017-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170087112-A1 COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF STROKE PMAIP1, EBP, PLAT PRKCA 13/4885PRKCG 18/4885PRKCB 40/4885
US-20200207698-A1 Compositions And Methods Of Use Of Phorbol Esters In The Treatment Of Neoplasms PMAIP1, MYD88, HRAS PRKCA 15/4885PRKCG 33/4885PRKCB 26/4885
US-10369222-B2 Compositions and methods of use of phorbol esters for the treatment of stroke PMAIP1, EBP, PLAT PRKCA 13/4885PRKCG 18/4885PRKCB 40/4885
US-20170096386-A1 Compositions And Methods Of Use Of Phorbol Esters For Treatment of Stroke PMAIP1, PLAT, EBP PRKCA 15/4885PRKCG 24/4885PRKCB 44/4885
US-20200207697-A1 Compositions And Methods Of Use Of Phorbol Esters For Treatment of Stroke PMAIP1, PLAT, EBP PRKCA 15/4885PRKCG 24/4885PRKCB 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.